PLK1 and posterior cortical atrophy: BI2536, which is an effective and selective ATP competitive PLK1 inhibitor, combines low-dose BI2536 with nocodazole (which synchronizes cells in the G2/M phase) to limit side effects and synergistically reduce cell growth and survival in advanced PCa cells (46).